On October 25, Guolonghui | CICC issued a research report pointing out that it is expected that Beigene will announce encouraging performance for the third quarter of the 2024 fiscal year. The bank pointed out that based on Beigene's BTK drug zanubrutinib expanding the regional coverage of indications for blood cancers to more overseas countries, it is expected that zanubrutinib's sales in the third quarter will increase by 94% annually or by 9% quarterly to 0.695 billion US dollars. CICC also expects that Beigene's total revenue for the third quarter will increase by 26% annually or by 6% quarterly to 0.982 billion US dollars. Assuming that the company's production efficiency improves in the fiscal years 2025 and 2026, the forecasted blended gross margin will increase by 2.1 and 3.5 percentage points respectively, driving the company's gross margin to reach 85.9% and 86.1% in the fiscal years 2025 and 2026, respectively. Considering the improvement in market sentiment, CICC raised the listed in Hong Kong target price for Beigene from 141 Hong Kong dollars to 175 Hong Kong dollars, maintaining an "outperform" rating.